Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience
Jeffrey Berinstein, Taylor A. Karl, Anish Patel, Michael T. Dolinger, Terrence A. Barrett, Waseem Ahmed, Ben Click, Calen A. Steiner, David Dulaney, Jake Levine, Syed Adeel Hassan, Courtney Perry, Deborah Flomenhoft, Ryan C. Ungaro, Elliot Berinstein, Jessica L. Sheehan, Shirley Cohen‐Mekelburg, Randolph E. Regal, Ryan W. Stidham, Shrinivas Bishu, Jean‐Frédéric Colombel, Peter Higgins
Abstract
INTRODUCTION: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy. METHODS: Patients with ASUC treated with upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions. RESULTS: Of the 25 patients with ASUC treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) of the 18 patients with available data and who did not undergo colectomy experienced steroid-free clinical remission (1 patient did not have complete data), 1 (4%) patient experienced a venous thromboembolic event, while 5 (20%) patients were readmitted. DISCUSSION: Upadacitinib along with intravenous corticosteroids may be an effective treatment for ASUC.